Angela Coliva
University of Milan
21 Papers
141 Citations
Angela Coliva is an academic researcher from University of Milan. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 10, co-authored 16 publications.
Chat about Author
Papers
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
Barbara Frigerio,Giulio Fracasso,Elena Luison,Sara Cingarlini,Mimosa Mortarino,Angela Coliva,Ettore Seregni,Emilio Bombardieri,Gaia Zuccolotto,Antonio Rosato,Marco Colombatti,Silvana Canevari,Mariangela Figini +12 more
TL;DR: A single-chain variable fragment engineered from the variable heavy and light domains of the murine anti-PSMA monoclonal antibody D2B has the potential to become a good theranostic reagent for early detection and therapy of prostate cancers.
57
90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas
Angela Coliva,Alberto Zacchetti,Elena Luison,Antonella Tomassetti,Italia Bongarzone,Ettore Seregni,Emilio Bombardieri,Franck Martin,Augusto Giussani,Mariangela Figini,Silvana Canevari +10 more
TL;DR: The feasibility of 90Y-labeling of MOv18 without compromising antibody binding ability and the immunoreagent-specific localization in vivo on FR-expressing tumors is demonstrated, suggesting the suitability of 90 Y-MOv18 for clinical studies.
45
Shed HER2 Extracellular Domain in HER2-Mediated Tumor Growth and in Trastuzumab
Francesca Bianchi,Manuela Campiglio,Mimosa Mortarino,Mariangela Figini,Angela Coliva,Maria Luisa Carcangiu,Milvia Zambetti,Tiziana Piazza,Silvano Ferrini,Elda Tagliabue,Serenella M. Pupa +10 more
- 01 Jan 2010
TL;DR: In this article, Liss et al. examined the biological effects exerted by elevated HER2/ECD in cancer growth and in response to Trastuzumab, showing that shed HER2 significantly blocked HER2-driven tumor cell proliferation.
31
Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
Gaia C. Ghedini,Valentina Ciravolo,Monica Tortoreto,Sarah Giuffré,Francesca Bianchi,Manuela Campiglio,Mimosa Mortarino,Mariangela Figini,Angela Coliva,Maria Luisa Carcangiu,Milvia Zambetti,Tiziana Piazza,Silvano Ferrini,Sylvie Ménard,Elda Tagliabue,Serenella M. Pupa +15 more
TL;DR: In this article, the authors examined the biological effects exerted by elevated HER2/ECD in cancer growth and in response to Trastuzumab using surface plasmon resonance analysis and showed that shed HER2 significantly blocked HER2-driven tumor cell proliferation.
27
Dosimetry in Myeloablative 90Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results
Carlo Chiesa,Francesca Botta,Erika Di Betta,Angela Coliva,Marco Maccauro,Gianluca Aliberti,Sergio Bavusi,Liliana Devizzi,Anna Guidetti,Ettore Seregni,Alessandro Massimo Gianni,Emilio Bombardieri +11 more
TL;DR: The theoretical investigation demonstrates that, in this particular case of (90)Y Zevalin therapy, the uncertainty about radiobiological parameters was not a limiting factor for a BED-based calculation of the maximum injectable activity.
22